Assess execution risk, data reliability, and inspection readiness before you commit and avoid costly surprises after signing.
Assess execution risk, data reliability, and inspection readiness before you commit and avoid costly surprises after signing.
↓ Tolerance
Less room for deal uncertainty
↓ ~20%
Biotech funding vs prior year
$137.7B
China out-licensing (2025)
The data package may look complete. What often remains unclear is how that data was generated, governed, and whether it will hold under tighter financial and regulatory expectations.
A complete dataset does not guarantee that it is traceable, consistent, or reconstructable under audit.
“Unknown” responses are not neutral, they indicate missing evidence and unresolved risk.
Site, subject, or country-level patterns may indicate risk that is not visible in topline results.
If oversight decisions and issue handling cannot be traced, the clinical story may not hold under inspection.
Without structured analysis, critical risks often surface post-signing, increasing remediation effort and delay.
If execution risk is unclear, timelines and valuation assumptions may be overly optimistic.
Clinical due diligence requires more than data review. It requires aligned expertise across data analysis, QA, and inspection readiness.
Are there gaps you cannot explain?
Do you need to rely on the existing trial without rework?
Are timelines and valuation assumptions critical?
Design out avoidable risk before FPFV. AI-augmented protocol analysis surfaces CtQs, quantifies complexity, predicts deviation hot-spots, and reduces amendment drag, so you lock in patient-safe, inspection-ready design from day one.
Operationalize RBQM with verifiable math. AI-guided RACTs, calculation transparency, RBAC-secured workflows, and cross-study analytics deliver proportionate controls, clear KRI/QTL governance, and faster, defensible decisions at scale.
Move beyond manual cleaning and fragmented reviews. With time-series anomaly detection, protocol-aware deviation checks, and structured reasoning, the MyRBQM® Portal highlights what truly requires attention.
Stay ahead of issues, not behind them. Portfolio-wide, AI-enhanced dashboards fuse KRIs, QTLs, and deviation signals to cut escalation latency and focus monitors on high-value actions, fully aligned with ICH expectations.
See the full patient story—fast. Subject Profiles synthesize visits, AEs, ConMeds, labs, and trendlines, accelerating case review and improving safety decisions with transparent traceability and RBAC-controlled access.
Fast, secure connectivity with your clinical platforms through ready-made endpoints and low-overhead, real-time or batch data sync.
Pre-engineered, validated connectors to major EDC systems — reducing integration time while enabling secure, real-time or scheduled data sync.
Seamlessly connect your enterprise data platforms with secure, governed, low-overhead sync — without restructuring your existing data lake.
Our platform and processes meet internationally recognized security, availability, and confidentiality standards. ISO 27001:2022 certification and SOC 2 examinations provide independently verified assurance of our information security controls.
Our clinical-grade AI is independently certified through Microsoft’s Healthcare AI program, ensuring transparent, human-guided oversight, responsible AI practices, and secure integration with Azure’s validated infrastructure.
The MyRBQM Portal is built in alignment with 21 CFR Part 11 and GAMP 5, ensuring data integrity, traceability, and suitability for use in regulated clinical research environments.
Use the scoring checklist to identify visibility gaps, evaluate risk, and determine whether the clinical package supports confident decision-making.
Industry Solutions
Featured Insights
Start Your Roll-Out
RBQM Capability Pathway
Quick Answers
Presented By
Dr. Artem Andrianov
Cyntegrity
Presented By
Shehnaz Vakharia
ADAMAS Consulting
From retrospective QA → to continuous, data-driven oversight
Date
April, 27th 2026
